Description: The presenter will share his opinion on the major and minor cycle of the global and China economy. He believes that the recovery of the major cycle depends on the resonance of politics between China and the United States, as well as reform. As the minor cycle is V-type, the weak recovery depends on policy and price increase. The liquidity regulation and the growth advance together. The economic cycle is stabilizing, monetary policy is tightening the margin and the importance of the regulation is increasing. But the increase of the economy is critical to risk controlling.

Description: The August/September 2015 edition of The Actuary magazine—the Society of Actuaries’ flagship publication.

Description: Though some defined contribution plans have added retirement income options in the form of annuities, there is a challenge to retirees in deciding whether to select such options and if so the amount to purchase. This article discusses a variety of considerations that retirees should be aware of when making a decision to annuitize.

Description: The article contains a description of the Emerging Topics Community. The focus of the article is what is a community, what makes the Emerging Topics Community special, and benefits of the Community. Included after the discussion on the community are ways to get involved and be a part of the community.

Description: Guidance and a model for actuaries to use when performing their professional services related to Medicaid (Title XIX) and Children’s Health Insurance Program (CHIP or Title XXI) managed care capitation rate setting.

Description: Discover the multitude of risk transfer solutions and payment models available to health claims payers for cell & gene therapies in this Society of Actuaries webinar. Delving deeper into the topic, we will examine the different types of solutions, weigh their pros and cons, and explore the future prospects of this rapidly evolving area of the healthcare landscape. By expanding upon the pricing and risk exposure discussion from session two, this webinar provides valuable insights into the dynamic market for cell & gene therapies and its implications for actuaries.

Description: Meet the authors of and learn about the contributors to the newly published e-book "Design Your Future with the Competency Framework." Presenters will share their personal reflections, stories and words of wisdom to bring to life the eight professional and personal competencies in the SOA Competency Framework.

Description: The Federal funds rate increased by 4.25% in 2022 with further increases in 2023, which have already resulted in a liquidity crisis for a few banks. As the rapid increase of the interest rates pushed the new money rates above the yields of many life insurers’ investment portfolios, insurance companies are facing a dilemma between compressed margins from peer pressure and the concern with liquidity shortfalls and realized capital losses should mass surrenders happen. This paper discussed main emerging risks under rising interest rate environment, and several ways to mitigate these risks.

Description: Investigate the importance of collaboration with accounting, underwriting, sales, marketing and other professions as an actuary when you attend this webcast. Cross-functional positions can cause unique challenges to arise, like various experts attempting to balance growth and profitability. Discover an opportunity to learn about relevant ASOPs and dive deeper into contemporary examples that highlight specific professionalism issues that can develop.

Description: Develop a better understanding of specialty drug trends and their increasing healthcare costs for more than the past decade by attending this webcast. With the introduction of price competition, you will see changes in the market for biosimilar products and patent-protected drugs. For example, the drug Humira will be gaining 10 biosimilar competitors in 2023. Alone, Humira can represent over 20% of total pharmacy spend for health plans. Join us and discover how price competition is a turning point for the pharmaceutical industry and will define its direction for the next decade.